PubRank

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Clinical Trial ID NCT02110082

PubWeight™ 16.77‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02110082

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015 2.25
2 Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015 1.10
3 Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016 1.06
4 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
5 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol 2015 0.97
6 The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016 0.93
7 Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) 2015 0.90
8 Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy. Front Immunol 2015 0.85
9 Principles of antibody-mediated TNF receptor activation. Cell Death Differ 2015 0.84
10 Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf) 2015 0.83
11 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother 2016 0.81
12 Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 2015 0.81
13 Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016 0.81
14 The emerging role of immunotherapy in colorectal cancer. Ann Transl Med 2016 0.80
15 Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015 0.78
16 CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy. Hum Vaccin Immunother 2015 0.75
17 Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects. Cancer Immunol Res 2016 0.75
18 Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. Oncoimmunology 2016 0.75
19 Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. Immunotargets Ther 2015 0.75
Next 100